RU2692789C2 - Соединение триазина и его применение в медицинских целях - Google Patents
Соединение триазина и его применение в медицинских целях Download PDFInfo
- Publication number
- RU2692789C2 RU2692789C2 RU2016137263A RU2016137263A RU2692789C2 RU 2692789 C2 RU2692789 C2 RU 2692789C2 RU 2016137263 A RU2016137263 A RU 2016137263A RU 2016137263 A RU2016137263 A RU 2016137263A RU 2692789 C2 RU2692789 C2 RU 2692789C2
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- compound
- mmol
- mixture
- pharmaceutically acceptable
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014-031035 | 2014-02-20 | ||
| JP2014031035 | 2014-02-20 | ||
| PCT/JP2015/054519 WO2015125842A1 (ja) | 2014-02-20 | 2015-02-19 | トリアジン化合物及びその医薬用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016137263A RU2016137263A (ru) | 2018-03-23 |
| RU2016137263A3 RU2016137263A3 (https=) | 2018-10-04 |
| RU2692789C2 true RU2692789C2 (ru) | 2019-06-27 |
Family
ID=53878341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016137263A RU2692789C2 (ru) | 2014-02-20 | 2015-02-19 | Соединение триазина и его применение в медицинских целях |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US20150266834A1 (https=) |
| EP (2) | EP3456713A1 (https=) |
| JP (4) | JP6461637B2 (https=) |
| KR (1) | KR102360699B1 (https=) |
| CN (1) | CN106232585B (https=) |
| AR (1) | AR099498A1 (https=) |
| AU (1) | AU2015219920B2 (https=) |
| BR (1) | BR112016018341B1 (https=) |
| CA (1) | CA2936408C (https=) |
| CL (1) | CL2016002091A1 (https=) |
| CY (1) | CY1121261T1 (https=) |
| DK (1) | DK3109240T3 (https=) |
| ES (1) | ES2704922T3 (https=) |
| HR (1) | HRP20182134T1 (https=) |
| IL (1) | IL247319B (https=) |
| LT (1) | LT3109240T (https=) |
| MX (1) | MX369217B (https=) |
| MY (1) | MY183605A (https=) |
| PE (2) | PE20211548A1 (https=) |
| PH (1) | PH12016501651B1 (https=) |
| PL (1) | PL3109240T3 (https=) |
| PT (1) | PT3109240T (https=) |
| RS (1) | RS58235B1 (https=) |
| RU (1) | RU2692789C2 (https=) |
| SA (1) | SA516371701B1 (https=) |
| SG (1) | SG11201606902QA (https=) |
| SI (1) | SI3109240T1 (https=) |
| SM (1) | SMT201800684T1 (https=) |
| TR (1) | TR201821158T4 (https=) |
| TW (1) | TWI651310B (https=) |
| WO (1) | WO2015125842A1 (https=) |
| ZA (1) | ZA201606449B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2772907C2 (ru) * | 2015-08-17 | 2022-05-27 | Джапан Тобакко Инк. | Соединение гидрокситриазина и его применение в медицинских целях |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI651310B (zh) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| WO2016101885A1 (en) * | 2014-12-24 | 2016-06-30 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
| JP6478255B2 (ja) * | 2015-03-04 | 2019-03-06 | 株式会社島津製作所 | 蛍光誘導体化試薬及びアミン分析方法 |
| KR20180037270A (ko) * | 2015-08-17 | 2018-04-11 | 니뽄 다바코 산교 가부시키가이샤 | 히드록시트리아진 화합물 및 그의 의약 용도 |
| EP3372589B1 (en) * | 2015-10-29 | 2021-10-20 | ASKA Pharmaceutical Co., Ltd. | Pyrimidine derivative |
| GB201603311D0 (en) * | 2016-02-25 | 2016-04-13 | Jakobsson Per Johan | New uses and methods |
| WO2018026798A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda modulators and methods of using same |
| JP7036792B2 (ja) * | 2016-08-01 | 2022-03-15 | アプティニックス インコーポレイテッド | スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用 |
| WO2019002183A1 (de) * | 2017-06-26 | 2019-01-03 | Merck Patent Gmbh | Verfahren zur herstellung substituierter stickstoffhaltiger heterocyclen |
| CN114502163A (zh) * | 2019-07-22 | 2022-05-13 | 安吉昂生物医药公司 | 作为rho相关卷曲螺旋激酶(rock)抑制剂的乙炔基杂环 |
| US11786538B2 (en) * | 2019-12-11 | 2023-10-17 | Somerset Therapeutics, Llc | Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties |
| KR102157466B1 (ko) * | 2020-05-19 | 2020-09-17 | 동아대학교 산학협력단 | 헥사하이드로트리아진 유도체를 포함하는 방광암의 예방, 개선 또는 치료용 조성물 |
| KR20230142739A (ko) | 2021-02-02 | 2023-10-11 | 아스카 세이야쿠 가부시키가이샤 | 피리미딘 유도체 |
| TW202409037A (zh) | 2022-07-06 | 2024-03-01 | 日商Ａｓｋａ製藥股份有限公司 | 嘧啶衍生物 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5955060A (en) * | 1995-11-23 | 1999-09-21 | Ciba Specialty Chemicals Corporation | Bis(resorcinyl)triazines useful as sunscreens in cosmetic preparations |
| WO2011037610A1 (en) * | 2009-09-23 | 2011-03-31 | Albert Einstein College Of Medicine Of Yeshiva University | Prostaglandin transporter inhibitors and uses thereof |
| EA201170095A1 (ru) * | 2008-06-26 | 2011-08-30 | Мицубиси Танабе Фарма Корпорейшн | Производные (4-пиридин-4-ил)-1h-(1,3,5) триазин-2-она в качестве ингибирования gsk3-бета для лечения нейродегенеративных заболеваний |
| RU2011125917A (ru) * | 2008-12-10 | 2013-01-20 | Топхарман Шанхай Ко., Лтд. | Производные фенилпиримидона, фармацевтические композиции, способы их получения и применения |
| WO2013087643A1 (en) * | 2011-12-12 | 2013-06-20 | Sanofi | 1,3,5 -triazine-2-amine derivatives, preparation thereof and diagnostic and therapeutic use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH473818A (de) | 1964-03-18 | 1969-06-15 | Ciba Geigy | Verfahren zur Herstellung von neuen Hydroxyphenyl-1,3,5-triazinen und deren Verwendung |
| EP0051067A1 (en) * | 1980-04-22 | 1982-05-12 | Commonwealth Scientific And Industrial Research Organisation | Triazine synthesis |
| SU1313854A1 (ru) | 1985-04-17 | 1987-05-30 | Институт Органической Химии Ан Армсср | Способ получени смеси 2-оксо-2,3-дигидро-4,6,-бис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина и 2,4,6-трис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина |
| US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| TW520362B (en) | 1996-12-05 | 2003-02-11 | Amgen Inc | Substituted pyrimidine compounds and pharmaceutical composition comprising same |
| AU733877C (en) * | 1996-12-05 | 2003-05-08 | Amgen, Inc. | Substituted pyrimidine compounds and their use |
| ZA9710727B (en) | 1996-12-05 | 1998-06-12 | Amgen Inc | Substituted pyrimidine compounds and methods of use. |
| US6410729B1 (en) | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
| GB9726987D0 (en) | 1997-12-22 | 1998-02-18 | Glaxo Group Ltd | Compounds |
| PL350884A1 (en) | 1999-04-01 | 2003-02-10 | Pfizer Prod Inc | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
| US20040082627A1 (en) * | 2002-06-21 | 2004-04-29 | Darrow James W. | Certain aromatic monocycles as kinase modulators |
| WO2008124092A2 (en) | 2007-04-03 | 2008-10-16 | E. I. Du Pont De Nemours And Company | Substituted benzene fungicides |
| BR122017025417B1 (pt) | 2008-06-04 | 2018-09-04 | Adeka Corp | Método para produção do composto 2,4,6-tri (hidroxifenil)-1,3,5-triazina |
| JP5388270B2 (ja) | 2008-06-04 | 2014-01-15 | 株式会社Ａｄｅｋａ | ２，４，６−トリス（ヒドロキシフェニル）−１，３，５−トリアジン化合物の製造方法 |
| AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| WO2011048004A1 (en) | 2009-10-23 | 2011-04-28 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin e2 synthase-1 |
| US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
| AR086254A1 (es) | 2011-05-26 | 2013-11-27 | Lilly Co Eli | Derivados de imidazol utiles para el tratamiento de artritis |
| PE20142098A1 (es) * | 2012-01-06 | 2015-01-08 | Agios Pharmaceuticals Inc | Compuestos terapeuticamente activos y sus metodos de uso |
| CA2873984A1 (en) | 2012-05-23 | 2013-11-28 | Stemergie Biotechnology Sa | Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| JP2014031035A (ja) | 2012-08-01 | 2014-02-20 | Yamaha Motor Co Ltd | 原動機付き鞍乗型車両 |
| WO2015059618A1 (en) * | 2013-10-22 | 2015-04-30 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS |
| TWI651310B (zh) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| CN105586773A (zh) * | 2014-11-13 | 2016-05-18 | 东丽纤维研究所（中国）有限公司 | 一种拒水抗紫外纺织品及其生产方法和用途 |
| KR20180037270A (ko) | 2015-08-17 | 2018-04-11 | 니뽄 다바코 산교 가부시키가이샤 | 히드록시트리아진 화합물 및 그의 의약 용도 |
| EP3372589B1 (en) * | 2015-10-29 | 2021-10-20 | ASKA Pharmaceutical Co., Ltd. | Pyrimidine derivative |
-
2015
- 2015-02-17 TW TW104105551A patent/TWI651310B/zh not_active IP Right Cessation
- 2015-02-19 PT PT15751885T patent/PT3109240T/pt unknown
- 2015-02-19 HR HRP20182134TT patent/HRP20182134T1/hr unknown
- 2015-02-19 JP JP2015030157A patent/JP6461637B2/ja active Active
- 2015-02-19 PL PL15751885T patent/PL3109240T3/pl unknown
- 2015-02-19 KR KR1020167025241A patent/KR102360699B1/ko not_active Expired - Fee Related
- 2015-02-19 MY MYPI2016703028A patent/MY183605A/en unknown
- 2015-02-19 PE PE2021000546A patent/PE20211548A1/es unknown
- 2015-02-19 SI SI201530563T patent/SI3109240T1/sl unknown
- 2015-02-19 EP EP18201469.6A patent/EP3456713A1/en not_active Withdrawn
- 2015-02-19 US US14/626,243 patent/US20150266834A1/en not_active Abandoned
- 2015-02-19 ES ES15751885T patent/ES2704922T3/es active Active
- 2015-02-19 AU AU2015219920A patent/AU2015219920B2/en not_active Ceased
- 2015-02-19 AR ARP150100484A patent/AR099498A1/es active IP Right Grant
- 2015-02-19 LT LTEP15751885.3T patent/LT3109240T/lt unknown
- 2015-02-19 CN CN201580020793.6A patent/CN106232585B/zh active Active
- 2015-02-19 RS RS20181563A patent/RS58235B1/sr unknown
- 2015-02-19 SM SM20180684T patent/SMT201800684T1/it unknown
- 2015-02-19 DK DK15751885.3T patent/DK3109240T3/en active
- 2015-02-19 CA CA2936408A patent/CA2936408C/en active Active
- 2015-02-19 WO PCT/JP2015/054519 patent/WO2015125842A1/ja not_active Ceased
- 2015-02-19 BR BR112016018341-0A patent/BR112016018341B1/pt not_active IP Right Cessation
- 2015-02-19 EP EP15751885.3A patent/EP3109240B1/en active Active
- 2015-02-19 PE PE2016001506A patent/PE20161236A1/es unknown
- 2015-02-19 SG SG11201606902QA patent/SG11201606902QA/en unknown
- 2015-02-19 RU RU2016137263A patent/RU2692789C2/ru active
- 2015-02-19 TR TR2018/21158T patent/TR201821158T4/tr unknown
- 2015-02-19 MX MX2016010875A patent/MX369217B/es active IP Right Grant
-
2016
- 2016-08-17 IL IL24731916A patent/IL247319B/en active IP Right Grant
- 2016-08-18 CL CL2016002091A patent/CL2016002091A1/es unknown
- 2016-08-18 SA SA516371701A patent/SA516371701B1/ar unknown
- 2016-08-18 PH PH12016501651A patent/PH12016501651B1/en unknown
- 2016-09-19 ZA ZA2016/06449A patent/ZA201606449B/en unknown
-
2018
- 2018-12-19 CY CY20181101359T patent/CY1121261T1/el unknown
- 2018-12-26 JP JP2018241974A patent/JP2019065036A/ja active Pending
-
2019
- 2019-04-26 US US16/396,503 patent/US20200087266A1/en not_active Abandoned
-
2021
- 2021-01-05 JP JP2021000347A patent/JP2021054856A/ja not_active Ceased
-
2022
- 2022-01-14 US US17/575,931 patent/US12398111B2/en active Active
- 2022-06-17 JP JP2022097960A patent/JP2022120173A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5955060A (en) * | 1995-11-23 | 1999-09-21 | Ciba Specialty Chemicals Corporation | Bis(resorcinyl)triazines useful as sunscreens in cosmetic preparations |
| EA201170095A1 (ru) * | 2008-06-26 | 2011-08-30 | Мицубиси Танабе Фарма Корпорейшн | Производные (4-пиридин-4-ил)-1h-(1,3,5) триазин-2-она в качестве ингибирования gsk3-бета для лечения нейродегенеративных заболеваний |
| RU2011125917A (ru) * | 2008-12-10 | 2013-01-20 | Топхарман Шанхай Ко., Лтд. | Производные фенилпиримидона, фармацевтические композиции, способы их получения и применения |
| WO2011037610A1 (en) * | 2009-09-23 | 2011-03-31 | Albert Einstein College Of Medicine Of Yeshiva University | Prostaglandin transporter inhibitors and uses thereof |
| WO2013087643A1 (en) * | 2011-12-12 | 2013-06-20 | Sanofi | 1,3,5 -triazine-2-amine derivatives, preparation thereof and diagnostic and therapeutic use thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2772907C2 (ru) * | 2015-08-17 | 2022-05-27 | Джапан Тобакко Инк. | Соединение гидрокситриазина и его применение в медицинских целях |
| RU2852458C1 (ru) * | 2021-02-02 | 2025-12-08 | Аска Фармасьютикал Ко., Лтд. | Производное пиримидина |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12398111B2 (en) | Triazine compounds and pharmaceutical use thereof | |
| CN108430994B (zh) | 用于调节cftr的化合物、组合物和方法 | |
| WO2003072532A1 (en) | Ester compound and medicinal use thereof | |
| US12492182B2 (en) | Hydroxytriazine compounds and pharmaceutical use thereof | |
| JPWO2005021486A1 (ja) | エステル誘導体及びその医薬用途 | |
| HK1228389B (en) | Triazine compound and use thereof for medical purposes | |
| HK1228389A1 (en) | Triazine compound and use thereof for medical purposes | |
| NZ721718B2 (en) | Triazine compound and use thereof for medical purposes | |
| AU2024314133A1 (en) | Combination therapies of fasn inhibitors with thyroid hormone receptor agonists | |
| RU2772907C2 (ru) | Соединение гидрокситриазина и его применение в медицинских целях | |
| HK40079824A (en) | Hydroxytriazine compounds and pharmaceutical use thereof |